Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 19, 2025Cardiovascular DiabetologyOpen Access

Risk of all–cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network

View Full Paper
Ask AI
Bookmark
Share

Authors

ETEnrico TartagliaTBTommaso BucciMRMichele Rossi

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals GLP-1 RA improves survival but raises acute pancreatitis risk in obesity and type 2 diabetes.

Key Points

  • To evaluate the risks of all-cause death and pancreatic events after initiating GLP-1 receptor agonists in obese and type 2 diabetes patients.
  • Conducted a retrospective study using TriNetX data from 2018 to 2024.
  • Divided participants into GLP-1 RA Users and Non–GLP-1 RA Users.
  • Calculated hazard ratios using Cox regression analyses and performed propensity score matching.
  • GLP-1 RA use significantly reduced all-cause death (HR 0.554).
  • Users experienced a slight increase in acute pancreatitis risk (HR 1.058).
  • Higher reduction in death noted in younger individuals (< 65 years).

Cite This Study

Tartaglia et al. (2025) studied this question.

synapsesocial.com/papers/6924fed1c0ce034ddc350f5ahttps://doi.org/10.1186/s12933-025-02986-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study2026 · 1 citations
  2. 2Glucagon-like Peptide-1 Receptor Agonists Are Not Associated with Increased Risk of Acute Pancreatitis or Pancreatic Complications, Including Pancreatic Cancer, in Type 2 Diabetes: A Global Propensity-Matched Cohort Study2026
  3. 3GLP-1 receptor agonist use and pancreatic cancer risk in patients with chronic pancreatitis.2026 · 1 citations
  4. 4GLP-1 receptor agonists and pancreatic cancer risk: A meta-analysis of real-world and trial evidence.2026
  5. 5Impact of glucagon-like peptide-1 receptor agonists on clinical outcomes in pancreatic cancer: A large-scale real-world cohort study.2026